TopPodcast.com
Menu
  • Home
  • Top Charts
  • Top Networks
  • Top Apps
  • Top Independents
  • Top Podfluencers
  • Top Picks
    • Top Business Podcasts
    • Top True Crime Podcasts
    • Top Finance Podcasts
    • Top Comedy Podcasts
    • Top Music Podcasts
    • Top Womens Podcasts
    • Top Kids Podcasts
    • Top Sports Podcasts
    • Top News Podcasts
    • Top Tech Podcasts
    • Top Crypto Podcasts
    • Top Entrepreneurial Podcasts
    • Top Fantasy Sports Podcasts
    • Top Political Podcasts
    • Top Science Podcasts
    • Top Self Help Podcasts
    • Top Sports Betting Podcasts
    • Top Stocks Podcasts
  • Podcast News
  • About Us
  • Podcast Advertising
  • Contact
Not in our directory?
Add Show Here
Podcast Equipment
Center

toppodcastlogoOur TOPPODCAST Picks

  • Comedy
  • Crypto
  • Sports
  • News
  • Politics
  • True Crime
  • Business
  • Finance

Follow Us

toppodcastlogoStay Connected

    View Top 200 Chart
    Back to Rankings Page
    Science

    New Retina Radio by Eyetube

    New Retina Radio is a place to hear stories about retina that are told nowhere else.

    Advertise

    Copyright: © 2020 Bryn Mawr Communications LLC

    • Apple Podcasts
    • Google Play
    • Spotify

    Latest Episodes:
    New Retina Radio Journal Club: Exudative AMD in FILLY and GATHER1 Results Sep 17, 2021
    Show notes

    As retina inches closer to a therapy that is safe and effective for the treatment of GA in the presence of dry AMD, the VBS Journal Club meets to review a pair of papers on a pair of pipeline treatments undergoing phase 3 evaluations. Aleksandra Rachitskaya, MD, is joined by Emmanuel Chang, MD, PhD; Michael Klufas, MD; and Dmitra Skondra, MD, to review phase 2/3 GATHER1 study, which is evaluating the safety and efficacy of avacincaptad pegol (Zimura, IVERIC bio). They also discuss a post hoc evaluation of the phase 2 FILLY study to determine which factors may be linked to the development of exudative AMD in some study patients after treatment with pegcetacoplan (Apellis), which is underdoing phase 3 investigation in the DERBY and OAKS studies.

    This editorially independent podcast is supported with advertising.


    The Art of Drug Choice: International Panel in Wet AMD: Safety Data Sep 10, 2021
    Show notes

    Safety will ultimately drive decision-making for patients with wet AMD. What are the latest safety data in the MERLIN, ARCHWAY, OPTIC, RGX-314, and TENAYA/LUCERNE trials? Moderator Arshad M. Khanani, MD, MA (United States), and panelists Justus G. Garweg, MD (Switzerland), Seenu M. Hariprasad, MD (United States), and Peter Kertes, MD, FRCSC (Canada), sift through the latest safety data to determine how concerns about safety could shape the future of wet AMD therapy.

    This editorially independent podcast is supported with advertising.


    Vitreous Opacities: Innovations and the Decision to Operate Sep 03, 2021
    Show notes

    Perspectives regarding surgery for vitreous opacities (VOs) have shifted in the past several years. How have innovations in surgical instrumentation, visualization, and IOL technology changed how surgeons approach VOs? John Kitchens, MD, sits down with S.K. Steven Houston III, MD, and Christina Weng, MD, MBA, to hear their perspectives on the modern state of VOs, learn about their surgical tactics, and establish how they determine when to send patients to surgery.

    This editorially independent podcast is supported with advertising.


    The Art of Drug Choice: International Panel in Wet AMD: The Pipeline Sep 01, 2021
    Show notes

    The pipeline of wet AMD treatments is inspiring. What can retina specialists around the world expect when it comes to wet AMD therapy candidates KSI-301 (Kodiak Sciences), RGX-314 (RegenxBio), and ADVM-022 (Adverum Biotechnologies)? Join moderator Arshad M. Khanani, MD, MA (United States), and panelists Justus G. Garweg, MD (Switzerland), Seenu M. Hariprasad, MD (United States), and Peter Kertes, MD, FRCSC (Canada), as they review early-phase data from some of the possible wet AMD drugs of the future.

    This editorially independent podcast is supported with advertising.


    International Perspectives: DME Aug 27, 2021
    Show notes

    In this opening installment of the New Retina Radio miniseries "International Perspectives," moderator Patricio Schlottmann (Argentina) sits down with panelists Catherine Creuzot-Garcher (France) and Adnan Tufail (United Kingdom) to review their strategies for treating patients with diabetic macular edema. The group discusses government regulations regarding the use of particular therapies and reviews why, in many cases, anti-VEGF therapy is the most effective therapeutic option.

    This editorially independent podcast is supported with advertising.


    The Art of Drug Choice: International Panel in Wet AMD: Phase 3 and Real-World Data to Watch Aug 20, 2021
    Show notes

    If new treatment options for wet AMD are approved for treatment, retina specialists will have even more options to switch patients to a new therapy. Which drug candidates have phase 3 data and real-world data that could point toward upcoming action by regulatory bodies? Arshad M. Khanani, MD, MA (United States), convenes an international panel comprised of Justus G. Garweg, MD (Switzerland), Seenu M. Hariprasad, MD (United States), and Peter Kertes, MD, FRCSC (Canada), to review data related to brolucizumab (Beovu, Novartis), the Port Delivery System with Ranibizumab (Genentech), and faricimab (Roche).

    This editorially independent podcast is supported with advertising.


    New Retina Radio Journal Club: Data in the Wake of COVID-19 Aug 13, 2021
    Show notes

    As the threat of COVID-19 subsides, scientists are working to make sense of the information that was gathered during the pandemic. Caroline Baumal, MD, asks M. Ali Khan, MD; Vlad Matei, MD; and Christina Weng, MD, MBA, to tackle two papers that analyze data collected during this time. First, they address the strengths and limits of a paper from the infectious disease realm that used history of AMD as a marker for complement inhibition in patients with COVID-19. Then, they parse the details of an article reviewing how real-world high-frequency patients with wet AMD fared when treatment intervals were increased during the height of the pandemic.

    This editorially independent podcast is supported with advertising.


    The Art of Drug Choice: International Panel in Wet AMD: When and Why Switching Therapy Makes Sense Aug 06, 2021
    Show notes

    Retina specialists around the world aim to reduce treatment burden while maximizing therapeutic outcomes in patients. How do global experts decide when to switch and to which therapy? Arshad M. Khanani, MD, MA (United States), is joined by Justus G. Garweg, MD (Switzerland), Seenu M. Hariprasad, MD (United States), and Peter Kertes, MD, FRCSC (Canada), to discuss tactics for moving wet AMD patients to new therapies or regimens. Also, Prof. Garweg shares a case of a patient who benefited from a new treatment option approved for wet AMD.

    This editorially independent podcast is supported with advertising.


    Surgical options for treating AMD: Clinical Implications and Impact Jul 29, 2021
    Show notes

    In the third episode of the Missing Link podcast series, Carl D. Regillo, MD, speaks with Carl Awh, MD, and Dante Pieramici, MD, about surgical options for neovascular AMD and how they might be applied in clinical practice. Although some of these options are still in the later stages of development, the panel looks forward to options that may truly change the treatment paradigm for the better. Click here to listen to this and other episodes in this series.

    This editorially independent podcast is supported with advertising.


    Advances in Gene Therapy for Wet AMD Jul 26, 2021
    Show notes

    In this roundtable moderated by Allen C. Ho, MD, experts in gene therapy discuss the latest data, clinical trial hurdles, and the promise these programs hold for patients being treated for wet AMD. Participants include Robert L. Avery, MD; Peter Campochiaro, MD, PhD; Jeffrey S. Heier, MD; Szilárd Kiss, MD; and Charles Wykoff, MD, PhD.

    This editorially independent podcast is supported with advertising.


    Previous 1 16 17 18 19 20 24 Next

    Related Podcasts

    Invisibilia

    1

    Invisibilia Personal Journals
    Hidden Brain – Hidden Brain, Shankar Vedantam

    2

    Hidden Brain – Hidden Brain, Shankar Vedantam Science
    How To Do Everything

    3

    How To Do Everything Science
    Hidden Brain

    4

    Hidden Brain Games & Hobbies
    Something You Should Know

    5

    Something You Should Know Education
    Sword and Scale – Sword and Scale

    6

    Sword and Scale – Sword and Scale Alternative Health
    footer-logo

    Contact Us

    Toll Free: 844-670-7747

    Links

    • Home
    • Top Charts
    • Networks
    • Apps
    • Independents Podcasts
    • Podcast Advertising
    • Podcast News
    • Contact Us
    • About Us
    • Analytics & Insights

    Stay Connected

      Privacy, Terms of Use & Our Code of Ethics Protecting Content Creators Copyrights